Loading...
•
Sep 30, 2021
Collegium Q3 2021 Earnings Report
Collegium reported third quarter results with net income of $8.0 million and adjusted EBITDA of $37.3 million. Board authorized $25 million accelerated share repurchase program.
Key Takeaways
Collegium Pharmaceutical reported its Q3 2021 financial results, featuring a net income of $8.0 million and an adjusted EBITDA of $37.3 million. The company's Board of Directors authorized a $25 million accelerated share repurchase program.
Collegium is on track to achieve record full year revenue, net income, and adjusted EBITDA.
Xtampza ER achieved 32.5% share of the ER oxycodone market, up 7.4 percentage points from year-end 2020.
Nucynta franchise net revenue grew to over $150 million year-to-date.
Company has sequentially reduced operating expenses, delivering on its commitment to leverage its cost structure.
Revenue by Segment
Forward Guidance
The company updated its full-year 2021 financial guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...